Dr. Cutler earned his Ph.D. at Johns Hopkins University Medical School and completed his postdoctoral fellowship in the Department of Pediatric Oncology at the Dana-Farber Cancer Institute. Dr. Cutler's focuses on studying an aggressive form of acute myeloid leukemia (AML) caused by chromosomal translocations involving the KMT2A/MLL1 gene (MLL-r) that produce MLL1 fusion oncoproteins. Specifically, Dr. Cutler is researching the interaction between the adapter protein Menin (MEN1) and MLL1 fusion proteins and how small molecules that disrupt this interaction, Menin inhibitors, inhibit leukemic transcription. 

Dr. Cutler has amassed expertise in a variety of technologies throughout his career, including flow cytometry, mass spectrometry-based proteomics, proximity-based proteomics, chromatin immunoprecipitation, CRISPR/Cas9-based genetic screening technologies, endogenous CRISPR-based editing of cell lines and developing knowledge of recombinant protein purifications. His goal is to establish an independent laboratory developing/employing cutting edge tools to uncover mechanisms of leukemia while mentoring the next generation of scientists and clinicians.